• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.苯丙烯酰胺衍生物AT - 61和AT - 130在体外可抑制野生型和拉米夫定耐药型乙型肝炎病毒株的复制。
Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60. doi: 10.1128/AAC.46.9.3057-3060.2002.
2
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.苯丙烯酰胺衍生物AT-61单独及与（-）β-L-2'，3'-二脱氧-3'-硫代胞苷联合使用对人乙型肝炎病毒复制的抑制作用
Antimicrob Agents Chemother. 1998 Dec;42(12):3179-86. doi: 10.1128/AAC.42.12.3179.
3
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.YMDD和rtA194T突变导致野生型乙肝病毒以及伴有前核心和核心启动子突变的乙肝病毒的复制能力下降。
Antivir Chem Chemother. 2011 Aug 23;22(1):13-22. doi: 10.3851/IMP1791.
4
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.拉米夫定耐药乙型肝炎病毒对阿德福韦和替诺福韦的体外敏感性
Antivir Ther. 2004 Jun;9(3):353-63.
5
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.乙肝病毒基因组中的基础核心启动子和前核心突变增强了拉米夫定耐药突变体的复制效力。
J Virol. 2004 Aug;78(16):8524-35. doi: 10.1128/JVI.78.16.8524-8535.2004.
6
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.乙型肝炎 e 抗原抑制突变对恩替卡韦耐药乙型肝炎病毒株复制效率的影响。
J Viral Hepat. 2011 Nov;18(11):804-14. doi: 10.1111/j.1365-2893.2010.01378.x. Epub 2010 Sep 30.
7
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.G1896A前核心突变对拉米夫定耐药乙型肝炎病毒体外药物敏感性和复制产量的影响。
Hepatology. 2003 Jan;37(1):27-35. doi: 10.1053/jhep.2003.50012.
8
Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.前核心和前S2基因组变化在拉米夫定耐药乙型肝炎病毒形成中所起的支持作用。
J Infect Dis. 2008 Oct 15;198(8):1150-8. doi: 10.1086/591941.
9
Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.新型氟核苷类似物 NCC 在肝细胞模型中抑制拉米夫定耐药的乙型肝炎病毒。
Braz J Infect Dis. 2018 Nov-Dec;22(6):477-486. doi: 10.1016/j.bjid.2018.11.005. Epub 2018 Dec 23.
10
Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.作为重叠S基因中突变的结果，通过病毒聚合酶“手指”亚结构域的补偿性变化恢复拉米夫定耐药乙型肝炎病毒突变体的复制表型。
Virology. 2002 Jul 20;299(1):88-99. doi: 10.1006/viro.2002.1448.

引用本文的文献

1
Machine Learning of Molecular Dynamics Simulations Provides Insights into the Modulation of Viral Capsid Assembly.分子动力学模拟的机器学习为病毒衣壳组装的调控提供了见解。
J Chem Inf Model. 2025 May 26;65(10):4844-4853. doi: 10.1021/acs.jcim.5c00274. Epub 2025 May 8.
2
Weighted Ensemble Simulations Reveal Novel Conformations and Modulator Effects in Hepatitis B Virus Capsid Assembly.加权集成模拟揭示了乙型肝炎病毒衣壳组装中的新构象和调节剂效应。
bioRxiv. 2025 Mar 17:2025.03.15.643452. doi: 10.1101/2025.03.15.643452.
3
Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression.秋水仙碱介导的乙肝病毒核心蛋白选择性自噬降解可抑制乙肝病毒复制及乙肝相关肝细胞癌进展。
Cell Death Discov. 2024 Aug 6;10(1):352. doi: 10.1038/s41420-024-02122-z.
4
Biophysics-Guided Lead Discovery of HBV Capsid Assembly Modifiers.基于生物物理学的乙肝病毒衣壳组装调节剂的先导化合物发现。
ACS Infect Dis. 2024 Apr 12;10(4):1162-1173. doi: 10.1021/acsinfecdis.3c00479. Epub 2024 Apr 2.
5
Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure.用于治愈慢性乙型肝炎（CHB）的乙型肝炎病毒（HBV）核心及衣壳组装调节剂（CAMs）的生物学特性
Glob Health Med. 2023 Aug 31;5(4):199-207. doi: 10.35772/ghm.2023.01065.
6
Targeting the HIV-1 and HBV Capsids, an EnCore.靶向 HIV-1 和 HBV 衣壳，一种 EnCore。
Viruses. 2023 Mar 31;15(4):896. doi: 10.3390/v15040896.
7
Molecular elucidation of drug-induced abnormal assemblies of the hepatitis B virus capsid protein by solid-state NMR.利用固态 NMR 技术对乙型肝炎病毒衣壳蛋白诱导的异常聚集进行分子解析。
Nat Commun. 2023 Jan 28;14(1):471. doi: 10.1038/s41467-023-36219-3.
8
Targeting Viral cccDNA for Cure of Chronic Hepatitis B.靶向病毒共价闭合环状DNA以治愈慢性乙型肝炎
Curr Hepatol Rep. 2020 Sep;19(3):235-244. doi: 10.1007/s11901-020-00534-w. Epub 2020 Jul 10.
9
Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action.新型 Neplanocin A 衍生物作为作用机制独特的乙型肝炎病毒选择性抑制剂。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0207321. doi: 10.1128/aac.02073-21. Epub 2022 May 23.
10
The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates.乙型肝炎病毒衣壳组装调节剂的作用机制可以通过与早期组装中间体的结合来预测。
J Med Chem. 2022 Mar 24;65(6):4854-4864. doi: 10.1021/acs.jmedchem.1c02040. Epub 2022 Mar 15.

本文引用的文献

1
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.乙型肝炎病毒对抗病毒药物的耐药性：当前情况及未来研究方向
Antivir Chem Chemother. 2001 Jan;12(1):1-35. doi: 10.1177/095632020101200101.
2
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.使用编码乙型肝炎病毒耐药株的新型重组杆状病毒进行抗乙肝病毒化合物的交叉耐药性检测。
Antimicrob Agents Chemother. 2001 Jun;45(6):1705-13. doi: 10.1128/AAC.45.6.1705-1713.2001.
3
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.
Gastroenterology. 2001 Mar;120(4):1000-8. doi: 10.1053/gast.2001.22454.
4
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.聚合酶区域中抗病毒耐药性人乙型肝炎病毒突变的命名法。
Hepatology. 2001 Mar;33(3):751-7. doi: 10.1053/jhep.2001.22166.
5
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.聚合酶L528M突变与核苷酸结合位点突变协同作用，增加乙肝病毒复制及耐药性。
J Clin Invest. 2001 Feb;107(4):449-55. doi: 10.1172/JCI11100.
6
Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
Bioorg Med Chem Lett. 2000 Dec 4;10(23):2687-90. doi: 10.1016/s0960-894x(00)00544-8.
7
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.具有稳定乙型肝炎病毒分泌功能的新型人肝癌细胞系的特性研究，用于评估针对拉米夫定和喷昔洛韦耐药病毒的新化合物。
Antimicrob Agents Chemother. 2000 Dec;44(12):3402-7. doi: 10.1128/AAC.44.12.3402-3407.2000.
8
Combination chemotherapy for hepatitis B virus: the path forward?乙型肝炎病毒的联合化疗：未来之路？
Drugs. 2000 Sep;60(3):517-31. doi: 10.2165/00003495-200060030-00001.
9
A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B.
Hepatology. 2000 Aug;32(2):413-7. doi: 10.1053/jhep.2000.9407.
10
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.拉米夫定长期治疗对亚洲慢性乙型肝炎患者的影响。亚洲拉米夫定肝炎研究小组。
Gastroenterology. 2000 Jul;119(1):172-80. doi: 10.1053/gast.2000.8559.

苯丙烯酰胺衍生物AT - 61和AT - 130在体外可抑制野生型和拉米夫定耐药型乙型肝炎病毒株的复制。

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.

作者信息

Delaney William E, Edwards Ros, Colledge Danni, Shaw Tim, Furman Phil, Painter George, Locarnini Stephen

机构信息

Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia.

出版信息

Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60. doi: 10.1128/AAC.46.9.3057-3060.2002.

DOI:10.1128/AAC.46.9.3057-3060.2002
PMID:12183271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC127422/
Abstract

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 +/- 9.5 and 2.40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

摘要

苯丙烯酰胺衍生物AT-61和AT-130是非核苷类乙型肝炎病毒（HBV）复制抑制剂。它们对野生型HBV复制的抑制浓度分别为21.2±9.5和2.40±0.92微摩尔，半数抑制浓度为50%，而拉米夫定的半数抑制浓度为0.064±0.020微摩尔。野生型和核苷类似物耐药（rtL180M、rtM204I和rtL180M + rtM204V）HBV之间的敏感性没有显著差异。